论文部分内容阅读
目的研究 CLLU1在慢性淋巴细胞白血病(CLL)患者中的表达及其与 CLL 临床分期、细胞遗传学异常、CD38和 ZAP-70之间的关系,并评价其预后意义。方法应用半定量 RT-PCR 技术检测 CLLUI 在50例 CLL 患者中的表达水平;应用三色流式细胞术检测 CLL 患者骨髓或外周血白血病细胞 ZAP-70和 CD38的表达;应用间期荧光原位杂交(FISH)技术检测 CLL 患者细胞遗传学异常。结果 50例 CLL 患者中有26例(52%)表达 CLLU1,其中7例(26.92%)在 Binet A 期,19例(73.08%)在 Binet B+C 期,二者表达差异有统汁学意义(P<0.01);24例 CD38~+CLL 患者中,17例(70.83%)CLLU1阳性表达,而在26例 CD38~-CLL 患者中,仪有9例(34.62%)CLLU1阳性表达,二者间差异有统计学意义(P<0.05);CLLU1在 ZAP-70阳性患者中的表达水平高于 ZAP-70阴性患者,但两组差异无统计学意义(P>0.05);未发现 CLLU1与细胞遗传学异常之间的相关性(P>0.05)。结论 CLLU1与临床分期、CD38密切相关,有可能作为 CLL 患者预后因素之一。
Objective To investigate the expression of CLLU1 in patients with chronic lymphocytic leukemia (CLL) and its relationship with clinical stage, cytogenetic abnormalities, CD38 and ZAP-70 in CLL and to evaluate its prognostic significance. Methods The expression of CLLUI in 50 CLL patients was detected by semi-quantitative RT-PCR. The expression of ZAP-70 and CD38 in bone marrow or peripheral blood leukemia cells of CLL patients was detected by three-color flow cytometry. Hybridization (FISH) technique to detect cytogenetic abnormalities in CLL patients. Results CLLU1 was expressed in 26 of 50 CLL patients (52%), of which 7 (26.92%) were in Binet A stage and 19 (73.08%) were in Binet B + C stage, with significant differences (P <0.01). Of the 24 patients with CD38 + CLL, 17 (70.83%) were positive for CLLU1, while 9 of 26 patients (34.62%) had positive expression of CLLU1 in 26 patients with CD38 ~ (P <0.05). The expression of CLLU1 in ZAP-70 positive patients was higher than that in ZAP-70 negative patients, but there was no significant difference between the two groups (P> 0.05). No correlation was found between CLLU1 and cells The correlation between genetic abnormalities (P> 0.05). Conclusion CLLU1 is closely related to clinical stage and CD38, which may be one of the prognostic factors of CLL.